{
    "organizations": [],
    "uuid": "30f2ead893db607ecc1e207633a9f7f8ecba73f9",
    "author": "",
    "url": "https://www.reuters.com/article/brief-immunogen-announces-first-patient/brief-immunogen-announces-first-patient-dosed-in-phase-1-study-of-imgn632-for-hematological-malignancies-idUSFWN1OZ0PR",
    "ord_in_thread": 0,
    "title": "BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 1:47 PM / Updated 9 minutes ago BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies Reuters Staff 1 Min Read \nJan 4 (Reuters) - ImmunoGen Inc: \n* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T15:46:00.000+02:00",
    "crawled": "2018-01-04T16:11:50.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "first",
        "patient",
        "dosed",
        "phase",
        "study",
        "imgn632",
        "hematological",
        "malignancy",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "immunogen",
        "inc",
        "immunogen",
        "announces",
        "first",
        "patient",
        "dosed",
        "phase",
        "study",
        "imgn632",
        "hematological",
        "malignancy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}